Sorrento Therapeutics (NASDAQ:SRNE) is a development stage biopharmaceutical company focused on the development and commercialization of proprietary drug therapeutics for cancer and cancer pain. The company is also developing therapeutic products for other indications, including inflammation, metabolic disorders, and infectious diseases.
Sorrento's pipeline consists of lead oncology product candidate Cynviloq™, a polymeric micellar nanoparticle paclitaxel formulation, resiniferatoxin (RTX), a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for cancer pain, as well as fully human therapeutic antibodies derived from its proprietary G-MAB® library platform and antibody drug conjugates (ADCs).
(click to enlarge)(click to enlarge)
Cynviloq, Next Generation of Abraxane®
Cynviloq is Sorrento's lead cancer drug candidate. Cynviloq™ is a next-generation nanoparticle
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|